The Patent Finder
MS

Merck Sharp and Dohme LLC

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Trius Therapeutics, Inc. (to 2016)

1,800 patents currently held

128 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
12 more records may belong here and await a decision; they are not counted.

The next term ends in Nov 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
518
Ending by 2030
Nov 2026
Next term end
1,508
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Antibodies to Human Programmed Death Receptor PD-1 US 8,354,509
The most cited patent in this portfolio, cited by 461 later US patents, top 1% of utility patents granted in 2013 in our data. Protection runs to 2028.
Ends Dec 2028 · High confidence
Also notable
Non-Immunostimulatory Antibody and Compositions Containing the Same US 7,700,099
Cited by 114 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Ends Jun 2027 · High confidence
Also notable
Tablet Formulation for CGRP Active Compounds US 10,117,836
Cited by 32 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Ends Jan 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Crystal Forms of a CCR5 Antagonist (US 10,301,281) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 9 fees due Dec 2 to 30, 2026 · next Dec 2
  • 25 fees due Jan 2 to 28, 2027 · next Jan 2
  • 22 fees due Feb 4 to 27, 2027 · next Feb 4
  • 31 fees due Mar 1 to 29, 2027 · next Mar 1
  • 26 fees due Apr 1 to 30, 2027 · next Apr 1
  • 23 fees due May 3 to 28, 2027 · next May 3
  • 28 fees due Jun 1 to 30, 2027 · next Jun 1
  • 35 fees due Jul 5 to 30, 2027 · next Jul 5
  • 20 fees due Aug 4 to 25, 2027 · next Aug 4
  • 30 fees due Sep 1 to 30, 2027 · next Sep 1
  • 20 fees due Oct 5 to 30, 2027 · next Oct 5
  • 18 fees due Nov 3 to 17, 2027 · next Nov 3

Which patents, and when each one lapses · Pro

Recent changes

  • 19 of the patents on this record were granted since Aug 23, 2026
  • 52 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,569,592Heteroaryl Substituted Pyrazole Modulators of Metabotropic Glutamate RECEPTOR-5
In force
 · High confidence
In forceHigh confidence
US 7,625,938Substituted Pyrazoles, Compositions Containing Such Compounds and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 7,618,985Isoquinoline Derivatives
In force
 · High confidence
In forceHigh confidence
US 8,486,983Self-Emulsifying Formulations of Cetp Inhibitors
In force
 · High confidence
In forceHigh confidence
US 7,528,132Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,298,543Identification and Application of Antibiotic Synergy
In force
 · High confidence
In forceHigh confidence
US 7,888,369Oxazoloisoquinoline Derivatives as Thrombin Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
US 7,547,720Ophthalmic Compositions for Treating Ocular Hypertension
In force
 · High confidence
In forceHigh confidence
US 7,709,658Process for Synthesizing a Substituted Pyrazole
In force
 · High confidence
In forceHigh confidence
US 7,834,026Spirocyclic Compounds
In force
 · High confidence
In forceHigh confidence
10 of 1,800 patents shown.
Pro members see all 1,800.
Pro members: see all 1,800 patents
Also on record, not counted in the 1,800: 128 patents in force now held by others · 1,689 patents ended · 401 applications pending · 1,237 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited